Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The study met its primary goal.
MAPLE-HCM study was designed to evaluate aficamten in patients with HCM compared to standard of care metoprolol. The primary endpoint was the change in peak oxygen uptake (pVO2) from baseline to Week 24. Data from the study showed statistically significant improvement in pVO2 in patients treated with aficamten compared to those who were on metoprolol.
Additionally, the safety and tolerability profile of aficamten was favorable in comparison to metoprolol in the study.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.